Pancreatica News Abstracts Archive - Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

Pancreas Cancer News and Archives

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients
With Cancer Based on the Modeling of Preclinical and Clinical
Pharmacokinetic and Pharmacodynamic Data

March 10, 2008

J Clin Oncol. 2008 Mar 10. [Epub] PMID: 18332467
[Abstract]

For educational purposes only; not to be relied upon
Please read Pancreatica Disclaimer

Home | In The News | Links | Donations
FAQ | Clinical Trials Database | Research Resources | About Us

webmaster

©2000-2008 Pancreatica.org - All Rights Reserved
www.pancreatica.org

	Pancreas Cancer News and Archives

	Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data March 10, 2008 J Clin Oncol. 2008 Mar 10. [Epub] PMID: 18332467 [Abstract]

	For educational purposes only; not to be relied upon Please read Pancreatica Disclaimer

	Home \| In The News \| Links \| Donations FAQ \| Clinical Trials Database \| Research Resources \| About Us

	webmaster

	©2000-2008 Pancreatica.org - All Rights Reserved www.pancreatica.org